Effectiveness of Danazol as an adjunctive therapy in dogs with immune-mediated hemolytic anemia
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Immune-mediated hemolytic anemia (IMHA) is autoimmune disease which is anemia caused by own immune system destroying the red blood cells (RBC). It can be diagnosed with spherocytosis, positive auto-agglutination of RBCs and direct antiglobulin test (DAT, Coomb’s test). The treatment for IMHA are blood transfusion, immunosuppressive agents including glucocorticoids and other supportive therapies. Danazol is synthetic androgen that has effect of interfering the autoimmune reaction to RBCs. It can be used as an adjunctive agent in addition to glucocorticoids. To investigate its effectiveness, the medical records of 10 IMHA-diagnosed dogs were evaluated. All subjects were treated with blood transfusion, prednisolone, mycophenolate mofetil, and intravenous human im-munoglobulin G. Additionally, 6 subjects were administered with danazol and 4 subjects were not. The results of initial blood examination and responses to the treatment for IMHA were compared between the groups. There were significant differences in the number of blood transfusions; once in group with danazol, twice in group without danazol, duration of recovery to normal hematocrit; 7.67±3.08 days in group with danazol, 22.00±5.66 days in group without danazol, and hospitalization; 5.17±0.75 days in group with danazol, 12.75±2.22 days in group without danazol. Therefore, danazol has potential effective on treating IMHA for rapid improvement.
Abstract
Immune-mediated hemolytic anemia (IMHA) is autoimmune disease which is anemia caused by own immune system destroying the red blood cells (RBC). It can be diagnosed with spherocytosis, positive auto-agglutination of RBCs and direct antiglobulin test (DAT, Coomb’s test). The treatment for IMHA are blood transfusion, immunosuppressive agents including glucocorticoids and other supportive therapies. Danazol is synthetic androgen that has effect of interfering the autoimmune reaction to RBCs. It can be used as an adjunctive agent in addition to glucocorticoids. To investigate its effectiveness, the medical records of 10 IMHA-diagnosed dogs were evaluated. All subjects were treated with blood transfusion, prednisolone, mycophenolate mofetil, and intravenous human im-munoglobulin G. Additionally, 6 subjects were administered with danazol and 4 subjects were not. The results of initial blood examination and responses to the treatment for IMHA were compared between the groups. There were significant differences in the number of blood transfusions; once in group with danazol, twice in group without danazol, duration of recovery to normal hematocrit; 7.67±3.08 days in group with danazol, 22.00±5.66 days in group without danazol, and hospitalization; 5.17±0.75 days in group with danazol, 12.75±2.22 days in group without danazol. Therefore, danazol has potential effective on treating IMHA for rapid improvement.
참고문헌 (15)
- Balch A, "Canine immune-mediated hemolytic anemia : pathophysiology, clinical signs, and diagnosis", Compendium(Yardley, PA), 29, pp.217~225 (2007)
- Balch A, "Canine immune-mediated hemolytic anemia : treatment and prognosis", Compendium(Yardley, PA), 29, pp.230~238 (2007)
- Bloom JC, "Use of danazol for treatment of corticosteroid-resistant immune-mediated thrombocytopenia in a dog", J Am Vet Med Assoc, 194, pp.76~78 (1989)
- Chai KY, "Danazol: an effective and underutilized treatment option in diamond-blackfan anaemia", Case Rep Hematol, pp.4684156~ (2019)
- Garden OA, "ACVIM consensus statement on the diagnosis of immune-mediated hemolytic anemia in dogs and cats", J Vet Intern Med, 33, pp.313~334 (2019)
- Goggs R, "Therapeutic strategies for treatment of immune-mediated hemolytic anemia", Vet Clin Small Anim, 50, pp.1327~1349 (2020)
- Grundy SA, "Influence of drug treatment on survival of dogs with immune-mediated hemolytic anemia : 88 cases(1989-1999)", J Am Med Assoc, 218, pp.543~546 (2001)
- Holloway SA, "Prednisolone and danazol for treatment of immune-mediated anemia, thrombocytopenia, and ineffective erythroid regeneration in a dog", J Am Vet Med Assoc, 197, pp.1045~1048 (1990)
- McCullough S, "Immune-mediated hemolytic anemia : understanding the nemesis", Vet Clin Small Anim, 33, pp.1295~1315 (2003)
- Miller E, "Danazol therapy for the treatment of immune-mediated hemolytic anemia in dogs(abstr)", J Vet Intern Med, 11, pp.130~ (1997)
- Piek CJ, "Idiopathic immune-mediated hemolytic anemia : treatment outcome and prognostic factors in 149 dogs", J Vet Intern Med, 22, pp.366~373 (2008)
- Reimer ME, "Immunemediated hemolytic anemia : 70 cases(1988-1996)", J Am Anim Hosp Assoc, 35, pp.384~391 (1999)
- Swann JW, "ACVIM consensus statement on the treatment of immune-mediated hemolytic anemia in dogs", J Vet Intern Med, 33, pp.1141~1172 (2019)
- Swann JW, "Systematic review of evidence relating to the treatment of immune-mediated hemolytic anemia in dogs", J Vet Intern Med, 27, pp.1~9 (2013)
- Whitley NT, "Immunomodulatory drugs and their application to the management of canine immune-mediated disease", J Small Anim Pract, 52, pp.70~85 (2011)